Compare · BIAF vs CRL
BIAF vs CRL
Side-by-side comparison of bioAffinity Technologies Inc. (BIAF) and Charles River Laboratories International Inc. (CRL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIAF and CRL operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- CRL is the larger of the two at $14.21B, about 4621.7x BIAF ($3.1M).
- CRL has been more active in the news (17 items in the past 4 weeks vs 12 for BIAF).
- CRL has more recent analyst coverage (25 ratings vs 0 for BIAF).
- Company
- bioAffinity Technologies Inc.
- Charles River Laboratories International Inc.
- Price
- -
- -
- Market cap
- $3.1M
- $14.21B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NYSE
- IPO
- 2022
- 2000
- News (4w)
- 12
- 17
- Recent ratings
- 0
- 25
Charles River Laboratories International Inc.
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains and purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets and chemical compounds through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company was founded in 1947 and is based in Wilmington, Massachusetts.
Latest BIAF
- bioAffinity Technologies Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026
- bioAffinity Technologies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung
- bioAffinity Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits
- WallachBeth Capital Announces Closing of bioAffinity Technologies $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
- bioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
- WallachBeth Capital Announces bioAffinity Technologies Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
- bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
- SEC Form 10-Q filed by bioAffinity Technologies Inc.
Latest CRL
- Chief Executive Officer Girshick Birgit gifted 528 shares, decreasing direct ownership by 1% to 35,485 units (SEC Form 4)
- CEVP, Disc & Safety Assessment Parisotto Shannon M exercised 2,039 shares at a strike of $194.12 and sold $599,711 worth of shares (2,039 units at $294.12) as part of a pre-agreed trading plan (SEC Form 4)
- Director Andrews Nancy C exercised 573 shares at a strike of $164.30 and sold $163,443 worth of shares (573 units at $285.24) (SEC Form 4)
- Charles River Laboratories and Medigen Vaccine Biologics Corp Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing
- Chief Executive Officer Girshick Birgit exercised 6,500 shares at a strike of $179.66 and sold $1,819,350 worth of shares (6,500 units at $279.90) as part of a pre-agreed trading plan (SEC Form 4)
- CEVP, Disc & Safety Assessment Parisotto Shannon M exercised 3,714 shares at a strike of $179.66 and sold $1,038,657 worth of shares (3,714 units at $279.66) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Charles River Laboratories International Inc.
- EVP, Corp Strategy & Develop Laplume Joseph W gifted 257 shares, decreasing direct ownership by 0.82% to 31,041 units (SEC Form 4)
- Director Foster James C exercised 28,733 shares at a strike of $179.66 and sold $7,901,575 worth of shares (28,733 units at $275.00) as part of a pre-agreed trading plan (SEC Form 4)
- SVP, Finance and CAO Knell Michael Gunnar sold $1,730,250 worth of shares (6,645 units at $260.38) and exercised 2,345 shares at a strike of $196.12, decreasing direct ownership by 27% to 11,852 units (SEC Form 4)